Correlation Between Metabolite of Prostaglandin E2 and the Incidence of Colorectal Adenomas

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Mar 16

PMID 36923425

Authors

Jia Jiang

Anjie Li

Xiaolian Lai

Hanqun Zhang

Chonghong Wang

Huimin Wang

Libo Li

Yuncong Liu

Lu Xie

Can Yang

Cui Zhang

Shuoyan Lu

Yong Li

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is a common malignancy, and the incidence and mortality rates continue to rise. An important factor in the emergence of inflammation-induced colorectal carcinogenesis is elevated cyclooxygenase-2. Prostaglandin E2 (PGE) over-production is frequently equated with cyclooxygenase-2 gene over-expression. PGE can be assessed by measuring the level of prostaglandin's main metabolite, PGE-M, in urine. Colorectal adenoma is a precancerous lesion that can lead to colorectal cancer. We conducted research to evaluate the association between urinary levels of the PGE-M and the risk of colorectal adenomas. In a western Chinese population, we identified 152 cases of adenoma and 152 controls patients without polyps. Adenoma cases were categorized into control, low-risk and high-risk groups. There was no significant change in PGE-M levels, between the control group and the low-risk adenoma group. In the high-risk group, the PGE-M levels were 23% higher than the control group. When compared to people with the lowest urine PGE-M levels (first quartile), people with greater urinary PGE-M levels had a higher chance of developing high-risk colorectal adenomas, with an adjusted odds ratio (95% CI) of 1.65 (0.76-3.57) in the fourth quartile group, (p= 0.013). We conclude urinary PGE-M is associated with the risk of developing high-risk adenomas. Urinary PGE-M level may be used as a non-invasive indicator for estimating cancer risk.

References

Gupta R, DuBois R . Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2002; 1(1):11-21. DOI: 10.1038/35094017. View

Gustafsson A, Andersson M, Lagerstedt K, Lonnroth C, Nordgren S, Lundholm K . Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2. Int J Oncol. 2010; 36(2):469-78. View

Wang D, DuBois R . Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila). 2013; 6(6):507-10. PMC: 3771525. DOI: 10.1158/1940-6207.CAPR-13-0153. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Schneider C, Pozzi A . Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev. 2011; 30(3-4):277-94. PMC: 3798028. DOI: 10.1007/s10555-011-9310-3. View

Wang D, Fu L, Sun H, Guo L, DuBois R . Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology. 2015; 149(7):1884-1895.e4. PMC: 4762503. DOI: 10.1053/j.gastro.2015.07.064. View

Steinbach G, Lynch P, Phillips R, Wallace M, Hawk E, Gordon G . The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000; 342(26):1946-52. DOI: 10.1056/NEJM200006293422603. View

Baron J, Cole B, Sandler R, Haile R, Ahnen D, Bresalier R . A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003; 348(10):891-9. DOI: 10.1056/NEJMoa021735. View

Salcedo R, Zhang X, Young H, Michael N, Wasserman K, Ma W . Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood. 2003; 102(6):1966-77. DOI: 10.1182/blood-2002-11-3400. View

10.

Johnson J, Schmidt C, Shrubsole M, Billheimer D, Joshi P, Morrow J . Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol. 2006; 4(11):1358-65. DOI: 10.1016/j.cgh.2006.07.015. View

11.

Sheng H, Shao J, Morrow J, Beauchamp R, DuBois R . Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58(2):362-6. View

12.

Cha Y, DuBois R . NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med. 2006; 58:239-52. DOI: 10.1146/annurev.med.57.121304.131253. View

13.

Eberhart C, Coffey R, Radhika A, Giardiello F, Ferrenbach S, DuBois R . Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107(4):1183-8. DOI: 10.1016/0016-5085(94)90246-1. View

14.

Gibbs D, Fedirko V, Baron J, Barry E, Flanders W, McCullough M . Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial. Cancer Prev Res (Phila). 2020; 14(1):65-76. PMC: 7947029. DOI: 10.1158/1940-6207.CAPR-20-0140. View

15.

Davenport J, Cai Q, Ness R, Milne G, Zhao Z, Smalley W . Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk. Mol Carcinog. 2015; 55(8):1251-61. PMC: 4816675. DOI: 10.1002/mc.22367. View

16.

Wang M, Honn K, Nie D . Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 2007; 26(3-4):525-34. DOI: 10.1007/s10555-007-9096-5. View

17.

Jara-Gutierrez A, Baladron V . The Role of Prostaglandins in Different Types of Cancer. Cells. 2021; 10(6). PMC: 8231512. DOI: 10.3390/cells10061487. View

18.

Katona B, Weiss J . Chemoprevention of Colorectal Cancer. Gastroenterology. 2019; 158(2):368-388. PMC: 6981249. DOI: 10.1053/j.gastro.2019.06.047. View

19.

Schottenfeld D, Beebe-Dimmer J . Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006; 56(2):69-83. DOI: 10.3322/canjclin.56.2.69. View

20.

Flossmann E, Rothwell P . Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369(9573):1603-13. DOI: 10.1016/S0140-6736(07)60747-8. View